Wall Street analysts forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will post earnings of ($0.22) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Inovio Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.29). Inovio Pharmaceuticals reported earnings per share of ($0.28) during the same quarter last year, which would indicate a positive year-over-year growth rate of 21.4%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Inovio Pharmaceuticals will report full-year earnings of ($0.88) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.71). For the next financial year, analysts expect that the firm will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.33) to ($1.04). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. The company’s revenue was up 229.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.26) EPS.

INO has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. BidaskClub upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research report on Tuesday, July 11th. Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Aegis restated a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $19.98.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of Inovio Pharmaceuticals in the second quarter worth $197,000. Wasatch Advisors Inc. increased its stake in shares of Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after buying an additional 793,306 shares during the period. Public Employees Retirement System of Ohio increased its stake in shares of Inovio Pharmaceuticals by 88.3% in the second quarter. Public Employees Retirement System of Ohio now owns 106,384 shares of the biopharmaceutical company’s stock worth $834,000 after buying an additional 49,897 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Inovio Pharmaceuticals by 1.7% in the second quarter. The Manufacturers Life Insurance Company now owns 54,670 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 897 shares during the period. Finally, BlueCrest Capital Management Ltd purchased a new position in shares of Inovio Pharmaceuticals in the second quarter worth $107,000. 24.83% of the stock is currently owned by institutional investors.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) opened at 6.29 on Thursday. The company’s market cap is $567.53 million. The company’s 50 day moving average is $6.13 and its 200 day moving average is $6.65. Inovio Pharmaceuticals has a one year low of $5.28 and a one year high of $9.86.

WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/12/0-22-eps-expected-for-inovio-pharmaceuticals-inc-ino-this-quarter-2.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.